Cempra is a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases. The Company's lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, for the treatment of community-acquired bacterial pneumonia, or CABP, one of the most serious infections of the respiratory tract in adults and children, as well as for ophthalmic infections and other indications.

Type
Public
HQ
Chapel Hill, US
Founded
2006
Size (employees)
45 (est)
Website
cempra.com
Cempra was founded in 2006 and is headquartered in Chapel Hill, US
Report incorrect company information

Key People/Management at Cempra

Prabhavathi Fernandes

Prabhavathi Fernandes

President & CEO
Mark Hahn

Mark Hahn

Evp & CFO
David Moore

David Moore

Evp & CCO

Cempra Office Locations

Cempra has an office in Chapel Hill
Chapel Hill, US (HQ)
360 6320 Quadrangle Dr
Show all (1)
Report incorrect company information

Cempra Financials and Metrics

Cempra Financials

Cempra's revenue was reported to be $18.02 m in FY, 2016 which is a 34% decrease from the previous period.
USD

Revenue (Q1, 2018)

14.8 m

Gross profit (Q1, 2018)

7.2 m

Gross profit margin (Q1, 2018), %

48.2%

Net income (Q1, 2018)

(29.4 m)

EBIT (Q1, 2018)

(43.6 m)

Market capitalization (18-Jun-2018)

251.1 m

Cash (31-Mar-2018)

91.5 m
Cempra's current market capitalization is $251.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

7.8 m15.2 m27.3 m18 m

Revenue growth, %

95%79%(34%)

General and administrative expense

9.4 m12.1 m22.9 m53.5 m

R&D expense

41.3 m62.5 m93.4 m81.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

1.2 m3.1 m1.9 m7.8 m5.1 m2.5 m2.7 m3.4 m4 m4.9 m860 k14.8 m

Cost of goods sold

7.7 m

Gross profit

7.2 m

Gross profit Margin, %

48%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

96.5 m99.1 m153.8 m231.6 m

Accounts Receivable

199.9 m

Inventories

7.5 m13.4 m

Current Assets

98.5 m104.9 m162 m238.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

110.4 m79.6 m68.6 m74.2 m202.4 m182 m223.6 m250.7 m248.9 m202.8 m187 m91.5 m

Inventories

28.2 m

Current Assets

111.7 m84.5 m72.9 m81.5 m207.9 m186.5 m228.7 m256.1 m254.2 m210.3 m190.4 m149.9 m

PP&E

2.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(45 m)(61.6 m)(91.1 m)(118 m)

Depreciation and Amortization

39.6 k76.3 k69.2 k51 k

Inventories

(617 k)(1.2 m)(153.6 m)5.2 m

Accounts Payable

4.1 m5.6 m(2.3 m)6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(28.2 m)(17 m)(33.4 m)(44.8 m)(42.4 m)(70 m)(29.4 m)(54.2 m)(86.5 m)(22.9 m)(35.2 m)(29.4 m)

Depreciation and Amortization

21.5 k14.5 k29.8 k44.9 k39.5 k54.4 k14.9 k30 k40 k9 k15 k4.8 m

Inventories

(2 m)

Accounts Payable

1.7 m2.5 m3.1 m4.5 m1.9 m3 m1.6 m4.9 m2.9 m(3.9 m)(8.9 m)4 m
USDY, 2018

Financial Leverage

2.2 x
Show all financial metrics
Report incorrect company information

Cempra Online and Social Media Presence

Embed Graph
Report incorrect company information

Cempra News and Updates

Report incorrect company information